BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• Biotech Bay

  Elan Corporation PLC Announces Pricing of New 2016 Senior Notes

  September 30, 2009

   · 

  1 min read
• Business

  BioRegion Rhine-Neckar-Triangle Association with New Management; Julia Schueler To Head Association

  September 30, 2009

   · 

  1 min read
• BioMidwest

  Arizona BioIndustry Association Announces Recipients of 2009 Awards

  September 30, 2009

   · 

  1 min read
• Drug Development

  InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting

  September 30, 2009

   · 

  2 min read
• Policy

  Labopharm Receives Notice of ANDA Submission with Paragraph IV Certification for Generic of Ryzolt(TM)

  September 30, 2009

   · 

  2 min read
• BioMidwest

  Cook Medical: Fertility and Reproductive Specialists Invited to Join Leading Research Scientist for Live Chat Event to Discuss Recent Advancements for In Vitro Maturation

  September 30, 2009

   · 

  1 min read
• Business

  OmniComm Systems, Inc.'s TrialMaster(TM) Added to Kendle International’s Suite of eClinical Solutions in Multi-Year Enterprise Agreement

  September 30, 2009

   · 

  3 min read
• Business

  Wyeth Pharmaceuticals (New Jersey) Initiates Phase II And Pays Ablynx Another Milestone of $4 Million In The Tnf-Alpha Nanobody(R) Collaboration

  September 30, 2009

   · 

  2 min read
• Tianyin Pharmaceutical Co, Inc. to Present at the Roth China Conference on October 14 at 12:30 pm ET

  September 30, 2009

   · 

  2 min read
• Pharm Country

  The Medicines Company Licenses Innovative New Formulation of Argatroban; Gains Strategic Complement to Angiomax Franchise and Potential Near Term Revenue Opportunity

  September 30, 2009

   · 

  4 min read